Idioma:

Effects of dapagliflozin in DAPA-HF according to background heart failure therapy

Docherty, Kieran F ; Jhund, Pardeep S ; Inzucchi, Silvio E ; Køber, Lars ; Kosiborod, Mikhail N ; Martinez, Felipe A ; Ponikowski, Piotr ; DeMets, David L ; Sabatine, Marc S ; Bengtsson, Olof ; Sjöstrand, Mikaela ; Langkilde, Anna Maria ; Desai, Akshay S ; Diez, Mirta ; Howlett, Jonathan G ; Katova, Tzvetana ; Ljungman, Charlotta E A ; O’Meara, Eileen ; Petrie, Mark C ; Schou, Morten ; Verma, Subodh ; Vinh, Pham Nguyen ; Solomon, Scott D ; McMurray, John J V

European heart journal, 2020-07, Vol.41 (25), p.2379-2392 [Periódico revisado por pares]

England: Oxford University Press

Texto completo disponível

Citações Citado por

Enviar para

Título:
Effects of dapagliflozin in DAPA-HF according to background heart failure therapy
Autor: Docherty, Kieran F ; Jhund, Pardeep S ; Inzucchi, Silvio E ; Køber, Lars ; Kosiborod, Mikhail N ; Martinez, Felipe A ; Ponikowski, Piotr ; DeMets, David L ; Sabatine, Marc S ; Bengtsson, Olof ; Sjöstrand, Mikaela ; Langkilde, Anna Maria ; Desai, Akshay S ; Diez, Mirta ; Howlett, Jonathan G ; Katova, Tzvetana ; Ljungman, Charlotta E A ; O’Meara, Eileen ; Petrie, Mark C ; Schou, Morten ; Verma, Subodh ; Vinh, Pham Nguyen ; Solomon, Scott D ; McMurray, John J V
Assuntos: Angiotensin Receptor Antagonists ; Benzhydryl Compounds ; Cardiac and Cardiovascular Systems ; Diuretics ; Editor's Choice ; Fast Track Clinical Research ; Glucosides - therapeutic use ; Heart failure ; Heart Failure - drug therapy ; Heart failure and reduced ejection fraction ; Humans ; Kardiologi ; SGLT2 inhibitor
É parte de: European heart journal, 2020-07, Vol.41 (25), p.2379-2392
Notas: ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Descrição: Abstract Aims In the DAPA-HF trial, the SGLT2 inhibitor dapagliflozin reduced the risk of worsening heart failure (HF) and death in patients with HF and reduced ejection fraction. We examined whether this benefit was consistent in relation to background HF therapy. Methods and results In this post hoc analysis, we examined the effect of study treatment in the following yes/no subgroups: diuretic, digoxin, mineralocorticoid receptor antagonist (MRA), sacubitril/valsartan, ivabradine, implanted cardioverter-defibrillating (ICD) device, and cardiac resynchronization therapy. We also examined the effect of study drug according to angiotensin-converting enzyme inhibitor/angiotensin receptor blocker dose, beta-blocker (BB) dose, and MRA (≥50% and <50% of target dose). We analysed the primary composite endpoint of cardiovascular death or a worsening HF event. Most randomized patients (n = 4744) were treated with a diuretic (84%), renin–angiotensin system (RAS) blocker (94%), and BB (96%); 52% of those taking a BB and 38% taking a RAS blocker were treated with ≥50% of the recommended dose. Overall, the dapagliflozin vs. placebo hazard ratio (HR) was 0.74 [95% confidence interval (CI) 0.65–0.85] for the primary composite endpoint (P < 0.0001). The effect of dapagliflozin was consistent across all subgroups examined: the HR ranged from 0.57 to 0.86 for primary endpoint, with no significant randomized treatment-by-subgroup interaction. For example, the HR in patients taking a RAS blocker, BB, and MRA at baseline was 0.72 (95% CI 0.61–0.86) compared with 0.77 (95% CI 0.63–0.94) in those not on all three of these treatments (P-interaction 0.64). Conclusion The benefit of dapagliflozin was consistent regardless of background therapy for HF.
Editor: England: Oxford University Press
Idioma: Inglês

Links

Voltar para lista de resultados

Realização: Logos de Redes Sociais:

Effects of dapagliflozin in DAPA-HF according to background heart failure therapy

England: Oxford University Press

Buscando em bases de dados remotas. Favor aguardar.